Clinical Trial Update: Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating sintilimab plus R-GemOx as second-line salvage therapy for relapsed/refractory diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• R-GemOx (rituximab, gemcitabine, oxaliplatin)
• Sintilimab (sintilimab)

Snippet

Sponsor: Qian Wenbin | Conditions: Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 2 | Status: UNKNOWN